Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

About this update from Rhythm Pharmaceuticals, Inc.

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher "AJ" Joshi, M.D., as Chief Medical Officer, effective August 17. "We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseases," said David Meeker, M.D., Rhythm Chairman, President and Chief Executive Officer. "AJ brings more than two decades of leadership and experience from discovery through pivotal trials, global regulatory processes and life-cycle management. His strategic vision and patient-centered approach will be invaluable as we advance our next-generation MC4R agonists through late-stage development and broaden our leadership in rare neuroendocrine diseases." Dr. Joshi said, "Rhythm has built something remarkable as the pioneer and leader in MC4R pathway diseases, with an approved medicine now reaching patients across multiple indications, and a a clinical pipeline that has the potential to help even more patients. Advancing rare disease therapies from development through approval has been the focus of my career. I look forward to bringing that expertise to Rhythm and working alongside the team to advance the development programs and reach even more patients and families around the world." Dr. Joshi joins Rhythm after serving as Chief Development Officer at Soleno Therapeutics. Previously, he was Chief Medical Officer of Neurona Therapeutics and held multiple leadership positions at Atara Biotherapeutics, including Executive Vice President, Chief Medical Officer and Head of Clinical Development. Earlier in his career, he held leadership roles spanning clinical development and medical affairs at Allergan Medical, Hunt Bioventures, Synageva BioPharma Corp., Genzyme and HealthBanks. Dr. Joshi received his B.A. and M.D. from Boston University and Boston University School of Medicine and completed his residency in Internal Medicine at Yale. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE® (setmelanotide), an MC...

View stock analysis, news, and events for Rhythm Pharmaceuticals, Inc.